サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1779929

糖尿病に伴う眼科治療の世界市場

Diabetes Associated Ophthalmic Treatment

出版日
ページ情報
英文 383 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.67円
糖尿病に伴う眼科治療の世界市場
出版日: 2025年07月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 383 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

糖尿病に伴う眼科治療の世界市場は2030年までに461億米ドルに到達

2024年に333億米ドルと推定される糖尿病に伴う眼科治療の世界市場は、2024～2030年の分析期間においてCAGR 5.6%で成長し、2030年には461億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである糖尿病性眼科治療薬は、CAGR 6.6%を記録し、分析期間終了時には289億米ドルに達すると予測されます。糖尿病眼科用機器セグメントの成長率は、分析期間中CAGR 4.0%と推定されます。

米国市場は91億米ドルと推定、中国はCAGR9.0％で成長予測

米国の糖尿病に伴う眼科治療市場は2024年に91億米ドルと推定されます。世界第2位の経済大国である中国は、2024～2030年の分析期間においてCAGR 9.0％を辿り、2030年までに94億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.6%と5.6%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の糖尿病に伴う眼科治療市場- 主要動向と促進要因まとめ

糖尿病に関連する視力障害はどのように緊急医療ニーズを生み出しているか？

糖尿病網膜症、糖尿病黄斑浮腫、緑内障など、糖尿病に関連する眼科疾患は、糖尿病の世界の有病率の上昇により、関心が高まっています。血糖値がコントロールされないと、網膜の繊細な血管が損傷し、視力低下が進行し、重症の場合は失明に至ります。特に高齢化社会と都市化社会における2型糖尿病の罹患率の増加が、先進的な眼科治療に対する需要に拍車をかけています。レーザー光凝固術などの従来の治療アプローチに加え、抗血管内皮増殖因子（抗VEGF）注射やコルチコステロイドインプラントなど、より革新的な治療が行われるようになり、視力維持における治療成績の向上が実証されています。光干渉断層計（OCT）や眼底写真などの画像診断技術の普及により、糖尿病性眼疾患の早期発見とより効果的な管理が可能になっています。さらに、糖尿病眼科医療に対する認識と政府の取り組みが高まるにつれ、より多くの患者がタイムリーな治療を求めるようになり、市場を牽引しています。

糖尿病患者の眼科治療における最新の技術革新とは？

糖尿病関連眼疾患の治療法は、生物学的製剤、低侵襲手術技術、徐放性ドラッグデリバリーシステムなどの進歩により、変貌を遂げつつあります。ラニビズマブやアフリベルセプトのような抗VEGF生物学的製剤の導入は、血管漏出を減少させ、疾患の進行を止めることによって、糖尿病黄斑浮腫の管理を著しく改善しました。さらに、コルチコステロイドをベースとした眼内インプラントは、少ない注射回数で長期的な軽減をもたらし、患者のコンプライアンスを向上させることができるため、人気を集めています。もう1つの有望な技術革新分野は遺伝子治療で、標的遺伝子の改変によって正常な網膜機能を回復させることを目的としています。網膜補綴物や、幹細胞を用いた介入を含む再生療法の開発も、重症例における視力回復に新たな道を開きつつあります。眼科における人工知能（AI）の出現は、特にスクリーニングと早期発見において、治療経路をさらに最適化し、臨床転帰を改善しています。製薬会社や医療機器会社が研究努力を強化する中、糖尿病関連眼科治療の将来はますます有望視されています。

眼科医療へのアクセス向上による市場の恩恵は？

糖尿病眼科治療における大きな変化の1つは、政府のヘルスケア・イニシアチブ、保険適用範囲の拡大、遠隔医療の技術進歩に後押しされた、治療へのアクセシビリティの向上です。AIを活用した診断ツールがプライマリ・ケアの現場に統合されることで、糖尿病網膜症の早期発見が可能になり、専門の眼科センターの負担が軽減されます。さらに、移動眼科診療ユニットや地域アウトリーチプログラムは、十分なサービスを受けていない人々にスクリーニングや治療サービスを提供する上で重要な役割を果たしています。眼科処置や薬物療法に対する償還政策の拡大は、より多くの患者が適時に治療を受けることをさらに促しています。糖尿病の有病率が急速に上昇している新興国では、国際的な協力関係や官民パートナーシップにより、先進的な眼科治療へのアクセスが向上しています。さらに、費用対効果の高い抗VEGF療法用バイオシミラーの開発により治療費が削減され、最先端の治療がより広く利用できるようになると期待されています。こうしたアクセシビリティの向上は、糖尿病患者の予防可能な失明を抑制する上で極めて重要な役割を果たしています。

糖尿病関連眼科治療市場の主な成長促進要因は？

糖尿病関連眼科治療市場の成長は、世界の糖尿病負担の増加、生物学的製剤の採用拡大、早期診断技術の進歩など、いくつかの要因によって牽引されています。糖尿病性眼疾患を発症するリスクが高い高齢者人口の増加は、市場拡大に大きく寄与しています。徐放性インプラントや遺伝子治療などのドラッグデリバリーの革新は、患者のアドヒアランスと臨床効果を向上させ、新規治療への需要をさらに押し上げています。また、眼科におけるAIの導入が進むことで、早期発見率が向上し、より積極的な治療アプローチにつながっています。さらに、眼科医療へのアクセシビリティの向上を目指した政府主導の啓発プログラムや政策改革が、市場成長に重要な役割を果たしています。遠隔眼科サービスの拡大やモバイル診断プラットフォームの普及は、特に農村部や低所得地域におけるヘルスケアの格差を埋めつつあります。さらに、製薬企業による眼科研究開発への投資の拡大とバイオシミラー競争の台頭は、先進治療をより安価なものにし、市場のさらなる拡大に拍車をかけています。継続的な技術革新と患者の意識の高まりにより、糖尿病関連眼科治療市場は今後数年間で持続的な成長を遂げる見通しです。

セグメント

タイプ（糖尿病眼科治療薬、糖尿病眼科治療機器）、用途（糖尿病網膜症用途、ドライアイ症候群用途、緑内障用途、眼アレルギー・感染症用途、その他用途）、最終用途（病院最終用途、眼科センター最終用途、外来センター最終用途、その他最終用途）

調査対象企業の例

  • Alcon Management S. A.
  • American Academy of Ophthalmology
  • Bausch+Lomb Corp.
  • Bausch Health Companies Inc.
  • Carl Zeiss Meditec AG
  • Eyenuk, Inc.
  • F. Hoffmann-La Roche Ltd.
  • IRIDEX Corporation
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30460

Global Diabetes Associated Ophthalmic Treatment Market to Reach US$46.1 Billion by 2030

The global market for Diabetes Associated Ophthalmic Treatment estimated at US$33.3 Billion in the year 2024, is expected to reach US$46.1 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Diabetic Ophthalmic Drugs, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$28.9 Billion by the end of the analysis period. Growth in the Diabetic Ophthalmic Devices segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.1 Billion While China is Forecast to Grow at 9.0% CAGR

The Diabetes Associated Ophthalmic Treatment market in the U.S. is estimated at US$9.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.4 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Diabetes Associated Ophthalmic Treatment Market - Key Trends & Drivers Summarized

How Is Diabetes-Linked Vision Impairment Creating Urgent Medical Needs?

Diabetes-associated ophthalmic conditions, including diabetic retinopathy, diabetic macular edema, and glaucoma, have become a growing concern due to the rising global prevalence of diabetes. Uncontrolled blood sugar levels damage the delicate blood vessels in the retina, leading to progressive vision loss and, in severe cases, blindness. The increasing incidence of type 2 diabetes, particularly in aging populations and urbanizing societies, has fueled the demand for advanced ophthalmic treatments. Conventional treatment approaches, such as laser photocoagulation, are now being supplemented by more innovative therapies, including anti-vascular endothelial growth factor (anti-VEGF) injections and corticosteroid implants, which have demonstrated improved outcomes in preserving vision. The growing accessibility of diagnostic imaging technologies, such as optical coherence tomography (OCT) and fundus photography, is enabling early detection and more effective management of diabetic eye diseases. Furthermore, with increasing awareness and government initiatives focusing on diabetic eye care, more patients are seeking timely treatment, driving the market forward.

What Are the Latest Innovations in Ophthalmic Treatments for Diabetic Patients?

The treatment landscape for diabetes-related eye diseases is undergoing a transformation, with advancements in biologics, minimally invasive surgical techniques, and sustained-release drug delivery systems. The introduction of anti-VEGF biologics, such as ranibizumab and aflibercept, has significantly improved the management of diabetic macular edema by reducing vascular leakage and halting disease progression. Additionally, corticosteroid-based intraocular implants are gaining popularity due to their ability to provide long-term relief with fewer injections, thereby improving patient compliance. Another promising area of innovation is gene therapy, which aims to restore normal retinal function through targeted genetic modifications. The development of retinal prosthetics and regenerative therapies, including stem cell-based interventions, is also opening new avenues for vision restoration in severe cases. The emergence of artificial intelligence (AI) in ophthalmology, particularly in screening and early detection, is further optimizing treatment pathways and improving clinical outcomes. With pharmaceutical and medical device companies intensifying research efforts, the future of diabetes-associated ophthalmic treatment looks increasingly promising.

How Is the Market Benefiting from Increased Accessibility to Eye Care?

One of the major shifts in diabetic eye care is the increased accessibility to treatment, driven by government healthcare initiatives, insurance coverage expansions, and technological advancements in telemedicine. The integration of AI-powered diagnostic tools into primary care settings allows for early identification of diabetic retinopathy, reducing the burden on specialized ophthalmology centers. Additionally, mobile eye care units and community outreach programs are playing a crucial role in bringing screening and treatment services to underserved populations. The expansion of reimbursement policies for ophthalmic procedures and drug therapies is further encouraging more patients to seek timely intervention. In emerging economies, where diabetes prevalence is rising rapidly, international collaborations and public-private partnerships are enhancing access to advanced ophthalmic treatments. Furthermore, the development of cost-effective biosimilars for anti-VEGF therapies is expected to reduce treatment costs, making cutting-edge care more widely available. These improvements in accessibility are playing a pivotal role in curbing preventable blindness among diabetic populations.

What Are the Key Growth Drivers of the Diabetes-Associated Ophthalmic Treatment Market?

The growth in the diabetes-associated ophthalmic treatment market is driven by several factors, including the rising global diabetes burden, increasing adoption of biologic therapies, and advancements in early diagnostic technologies. The growing geriatric population, which is at a higher risk of developing diabetic eye diseases, is significantly contributing to market expansion. Innovations in drug delivery, such as sustained-release implants and gene therapy, are improving patient adherence and clinical efficacy, further boosting demand for novel treatments. The increasing deployment of AI in ophthalmology is also enhancing early detection rates, leading to more proactive treatment approaches. Additionally, government-led awareness programs and policy reforms aimed at improving eye care accessibility are playing a crucial role in market growth. The expansion of teleophthalmology services and the proliferation of mobile diagnostic platforms are bridging healthcare gaps, particularly in rural and low-income regions. Moreover, the growing investments by pharmaceutical companies in ophthalmic R&D and the rise of biosimilar competition are making advanced treatments more affordable, fueling further market expansion. With continuous innovation and increasing patient awareness, the diabetes-associated ophthalmic treatment market is poised for sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Diabetes Associated Ophthalmic Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Diabetic Ophthalmic Drugs, Diabetic Ophthalmic Devices); Application (Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy and Infection Application, Other Applications); End-Use (Hospitals End-Use, Ophthalmic Centers End-Use, Ambulatory Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Alcon Management S. A.
  • American Academy of Ophthalmology
  • Bausch + Lomb Corp.
  • Bausch Health Companies Inc.
  • Carl Zeiss Meditec AG
  • Eyenuk, Inc.
  • F. Hoffmann-La Roche Ltd.
  • IRIDEX Corporation
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Diabetes Associated Ophthalmic Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Diabetes Throws the Spotlight on Ophthalmic Complications and Treatment Demand
    • Increased Screening and Early Diagnosis Spur Demand for Therapeutics Addressing Diabetic Retinopathy and Macular Edema
    • Growth in Anti-VEGF Therapy Adoption Strengthens the Business Case for Intravitreal Injections and Specialty Drugs
    • Expansion of Retinal Imaging and OCT Technology Enhances Precision in Monitoring Disease Progression
    • Digital Health and AI-Based Diagnostic Tools Accelerate Personalized Care in Diabetic Eye Disease Management
    • Integration of Teleophthalmology in Rural and Underserved Areas Improves Access to Retinal Screenings
    • Growing Use of Combination Therapies and Sustained-Release Implants Enhances Treatment Efficacy and Compliance
    • Reimbursement Policies and National Health Guidelines Drive Uptake of Retinopathy Treatments in Public Healthcare
    • Development of Non-Invasive Delivery Methods and Oral Agents Represents Next Frontier in Treatment Innovation
    • Ongoing Research in Neuroprotective and Anti-Inflammatory Agents Expands the Pipeline Beyond Vascular Targets
    • Patient Education and Awareness Campaigns Support Early Intervention and Regular Eye Exams
    • Rising Geriatric and Type 2 Diabetes Populations Sustain Long-Term Growth in Ophthalmic Interventions
    • Emerging Markets With High Diabetic Burden Offer Substantial Untapped Opportunities for Ophthalmic Drug Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Diabetes Associated Ophthalmic Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diabetic Ophthalmic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diabetic Ophthalmic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Diabetic Ophthalmic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diabetic Ophthalmic Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diabetic Ophthalmic Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Diabetic Ophthalmic Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Ambulatory Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Ambulatory Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Ambulatory Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Ophthalmic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Ophthalmic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Ophthalmic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diabetic Retinopathy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diabetic Retinopathy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Diabetic Retinopathy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Dry Eye Syndrome Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Dry Eye Syndrome Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Dry Eye Syndrome Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Glaucoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Glaucoma Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Glaucoma Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Eye Allergy & Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Eye Allergy & Infection Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Eye Allergy & Infection Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Diabetes Associated Ophthalmic Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Diabetes Associated Ophthalmic Treatment by Type - Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Type - Percentage Breakdown of Value Sales for Diabetic Ophthalmic Drugs and Diabetic Ophthalmic Devices for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Diabetes Associated Ophthalmic Treatment by End-Use - Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by End-Use - Percentage Breakdown of Value Sales for Ambulatory Centers End-Use, Other End-Uses, Hospitals End-Use and Ophthalmic Centers End-Use for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Diabetes Associated Ophthalmic Treatment by Application - Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Diabetes Associated Ophthalmic Treatment by Application - Percentage Breakdown of Value Sales for Diabetic Retinopathy Application, Dry Eye Syndrome Application, Glaucoma Application, Eye Allergy & Infection Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION